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Available online 29 October 2010AbstractCardiac vegetations result from bacteriumeplatelet adherence, activation and aggregation, and are associated with increased morbidity and
mortality in infective endocarditis. The GPIIb/IIIa and FcgRIIa platelet receptors play a central role in platelet adhesion, activation and
aggregation induced by endocarditis pathogens such as Staphylococcus aureus, but the influence of known polymorphisms of these receptors on
the pathogenesis of infective endocarditis is unknown. We determined the GPIIIa platelet antigen PlA1/A2 and FcgRIIa H131R genotype of
healthy volunteers (n ¼ 160) and patients with infective endocarditis (n ¼ 40), and investigated the influence of these polymorphisms on clinical
outcome in infective endocarditis and S. aureuseplatelet interactions in vitro. Platelet receptor genotype did not correlate with development of
infective endocarditis, vegetation characteristics on echocardiogram or the composite clinical end-point of embolism, heart failure, need for
surgery or mortality (P > 0.05 for all), even though patients with the GPIIIa PlA1/A1 genotype had increased in vivo platelet activation
(P ¼ 0.001). Furthermore, neither GPIIIa PlA1/A2 nor FcgRIIa H131R genotype influenced S. aureus-induced platelet adhesion, activation or
aggregation in vitro (P > 0.05). Taken together, our data suggest that the GPIIIa and FcgRIIa platelet receptor polymorphisms do not influence S.
aureuseplatelet interactions in vitro or the clinical course of infective endocarditis.
 2010 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
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Infective endocarditis is a life-threatening condition result-
ing from infection of native and prosthetic heart valves,
implantedmedical devices and large vessels [1]. In recent years,
Staphylococcus aureus has overtaken viridans streptococci as
the commonest causative agent, accounting for up to 49% of
cases [2,3]. This is worrisome as S. aureus infective endocarditis
has mortality rates as high as 56% [4], and underlying cardiac
risk factors cannot be identified in over 50% of patients [2].* Corresponding author. Tel.: þ44 131 242 9376; fax: þ44 131 242 9385.
E-mail address: ross.fitzgerald@ed.ac.uk (J.R. Fitzgerald).
1286-4579/$ - see front matter  2010 Institut Pasteur. Published by Elsevier Ma
doi:10.1016/j.micinf.2010.10.016Vegetations containing bacteria, fibrin and activated plate-
lets [5e7], are identified in up to 95% of patients with
infective endocarditis, with increased vegetation size associ-
ated with embolism and mortality [8e10]. When encased in
vegetations, bacteria are able to evade the host immune system
and antibiotic therapies, while still being able to grow and
disseminate [5e7]. Bacteria stimulate platelet aggregation
leading to vegetation formation through the initial binding of
microbial surface components recognizing adhesive matrix
molecules (MSCRAMMs) to platelet glycoprotein receptors
GPIIb/IIIa or GPIb via plasma protein cross-bridges [11]. The
subsequent cross-linking of specific immunoglobulins bound
to these MSCRAMMs with the FcgRIIa receptor on the
platelet surface results in platelet activation, followed bysson SAS. All rights reserved.
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bridges between GPIIb/IIIa receptors [11].
GPIIb/IIIa is a heterodimeric integrin protein linked non-
covalently by disulphide bridges [12]. It is the most abundant
platelet receptor with 80,000 copies per platelet, and is impli-
cated in platelet aggregation induced by a range of agonists [12].
First described in 1989, the GPIIIa platelet antigen (PlA1/A2)
polymorphism consists of a thymine to cytosine substitution at
nucleotide 1565 that modulates myosin light chain dephos-
phorylation, resulting in increased ‘outside-in’ signaling
[13,14]. Previous studies have identified enhanced platelet
aggregation in response to pharmacological agonists, and
increased susceptibility to vascular and immune disease in PlA2
carriers [15e17]. It is feasible that the PlA2 allele is also asso-
ciated with enhanced bacteriumeplatelet interactions, vegeta-
tion formation and adverse outcome in infective endocarditis.
FcgRIIa is a low affinity IgG-Fc receptor, numbering
between 1300 and 8500 on the platelet surface [18,19].
A functional polymorphism resulting from a G to A point
mutation leads to an arginine (R) to histidine (H) change at
position 131, with codominant expression of both alleles
[19,20]. The H131 allotype exhibits increased binding to
human IgG2 and IgG3 and has been associated with the devel-
opment of systemic lupus erythematosus on meta-analysis
[19,20]. However, the influence of this polymorphism on
susceptibility to infective endocarditis is unknown.
In as much as bacteriumeplatelet interactions are central to
the pathogenesis of infective endocarditis, we examined the
influence of the GPIIIa PlA1/A2 and the FcgRIIa H131R
platelet receptor polymorphisms on S. aureus-induced platelet
adhesion, activation and aggregation in vitro and clinical
outcome in patients with infective endocarditis.
2. Materials and methods2.1. SubjectsOne hundred and sixty healthy volunteers with no evidence
of clinically significant co-existing conditions, recent infection
or drug therapy were recruited in Edinburgh between July
2007 and March 2009. Forty patients admitted to Edinburgh
Royal Infirmary with a diagnosis of infective endocarditis
fulfilling the modified Duke criteria [21], were recruited
between November 2006 and March 2009. Exclusion criteria
included age less than 18 y and inability to provide consent.
Written informed consent was obtained from all participants
and all studies were conducted following approval from the
Lothian NHS Research Ethics Committee and in accordance
with the 1964 Declaration of Helsinki.2.2. Clinical outcomes and definitionsData for patients with infective endocarditis were collected
prospectively for the index presentation. The diagnosis of
embolism was based on clinical examination and non-invasive
radiological examinations were performed at the lead clini-
cian’s discretion. Cutaneous manifestations were excluded, astheir etiology is considered multifactorial [22]. Systematic
computed tomography surveillance for embolism was not
performed. The composite clinical end-point was defined as
the presence of embolism, heart failure, need for surgery or
death in patients with infective endocarditis within 3 months
of diagnosis.2.3. EchocardiographyEchocardiographic images were acquired from trans-
thoracic and/or transesophageal windows performed during
the acute phase of the infective endocarditis process using 2-
dimensional transducers capable of second and ultra-harmonic
imaging, attached to either Vingmed (GE Healthcare, Bedford,
UK) or iE33 (Philips, Surrey, UK) platforms. All data were
stored digitally. Transthoracic and transesophageal echocar-
diographic images were independently reviewed on EchoPAC
v 7.0.1 for the PC (GE Healthcare Vingmed Ultrasound,
Bedford, UK) by two experienced observers (DKD and GJP)
who were blinded to subject data including clinical history and
platelet receptor genotype. Vegetations were identified as
distinctly abnormal echogenic masses attached to the endo-
thelial surface of valves or endocardium. The largest length
and width obtainable in any one frame throughout the cardiac
cycle was measured for the largest vegetation if more than one
vegetation was present [9].2.4. Blood samplingVenepuncture was performed using a 19-gauge (1.1 mm)
needle or a 7 French (2.3 mm) triple-lumen central venous
catheter in situ. Care was taken to ensure a smooth blood draw
with minimal trauma. Where blood was sampled from
a central venous catheter, the initial 10 ml was discarded to
minimize sample contamination with heparin. Venous blood
(9 ml) was drawn into tubes containing ethylenediamine tet-
raacetic acid at a final concentration of 1.6 mg/ml for geno-
typing of platelet receptor polymorphisms in both healthy
volunteers and patients with infective endocarditis. Venous
blood (3 ml) was drawn into tubes containing 75 mM D-phe-
nylalanyl-L-propyl-L-arginine chloromethylketone (Haemato-
logic Technologies Inc, VT, USA) for determination of platelet
activation in patients with infective endocarditis.
Blood samples for isolation of platelet-rich plasma (PRP) for
platelet aggregometry and flow cytometry were taken from
selected healthy volunteers into 50 ml syringes containing
0.38% (w/v) sodium citrate. For the isolation of washed plate-
lets, blood from healthy subjects was drawn into 50 ml syringes
containing 15% (w/v) acid-citrate dextrose (7.32 g/l citric acid
anhydrous, 22 g/l sodium citrate, 24.52 g/l dextrose). PRP and
washed platelets were generated as described below.2.5. Platelet receptor polymorphism genotypingGenomic DNA was extracted from blood using the
NucliSens easyMag kit (BioMerieux, Basingstoke, UK)
according to the manufacturer’s instructions and adjusted to
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GPIIIa PlA1/A2 (rs5918) and FcgRIIa H131R (rs1801274)
polymorphisms were determined with the ABI 7900HT
Sequence Detection System (Applied Biosystems, Warrington,
UK) with proprietary oligonucleotide sequences and TaqMan
probes (Applied Biosystems, Warrington, UK).2.6. Generation of PRP and washed plateletsCitrated blood from healthy volunteers was centrifuged at
150g for 10 min to generate PRP. The PRP fraction was
removed and an aliquot was further centrifuged at 1500g for
10 min to generate platelet-poor plasma (PPP). Autologous PPP
was used to standardize PRP to a platelet count of 200  109/l
after the platelet count was determined on a Coulter A.T
series analyzer (Beckman Coulter Inc., High Wycombe, UK).
For preparation of washed platelets, PRPwas generated from
blood anticoagulated with acid-citrate dextrose and adjusted to
a pH of 6.5 with acid-citrate dextrose, prior to addition of 1 mM
prostaglandin E1 (Sigma, Dorset, UK) and 1 U/ml apyrase
(Sigma, Dorset, UK). Samples were centrifuged at 720g for
10 min to obtain a platelet pellet, which was gently resuspended
in modified HEPES-Tyrode’s (JNL) buffer (6 mM dextrose,
130 mM NaCl, 9 mM NaHCO3, 10 mM sodium citrate, 10 mM
TRIS-base, 3 mM KCl, 0.8 mM KH2PO4, 0.9 mM MgCl2; pH
7.4) [23]. Washed platelet suspensions were standardized to
a platelet count of 200  109/l in JNL buffer, with addition of
1 mg/ml human fibrinogen (Calbiochem, Nottingham, UK) and
2 mM Ca2þ.
All platelet preparations were used within 2.5 h of
venepuncture.2.7. Bacterial strain preparationS. aureus strain Newman and clinical infective endocarditis
S. aureus strains 207 and 209 [25] were grown to stationary
and exponential phase in braineheart infusion (BHI) broth
(Oxoid, Basingstoke, UK) at 37 C with constant rotation at
200 rpm. Bacterial growth was assessed by measurement of
the optical density at 600 nm (OD600) using a spectropho-
tometer (Cecil Aurius CE2021, Thistle Scientific Ltd., Glas-
gow, UK). Stationary phase was defined as an OD600 value
greater than 12 following culture for 16 h, while exponential
phase was defined as an OD600 value of between 0.5 and 0.9.
For platelet activation and aggregation studies, bacterial
cultures were washed twice in phosphate-buffered saline
(PBS) and resuspended to an OD600 value of 1.6. For S. aur-
euseplatelet adhesion studies, cultures were washed twice in
cold 0.05 M TriseHCl buffer containing 0.1 M NaCl and
0.02 M ethylenediamine tetraacetic acid, pH 7.25. Bacteria
were labeled with 100 mg/ml of Hoechst 33342 (Sigma,
Dorset, UK) before incubation in the dark for 2 h at 4 C,
followed by twice washing in Tyrode’s solution (137 mM
NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 0.2 mM
Na2HPO4, 12 mM NaHCO3, 5.5 mM dextrose, pH 7.4) and
resuspension to an OD600 of 1.6 [24].2.8. Platelet aggregometryPlatelet aggregometry was performed as described previ-
ously [25]. Briefly, 5  107 bacterial cells (in 25 ml PBS) were
added to 4.5  107 platelets (in 225 ml PRP or washed
platelets) in siliconized glass cuvettes with constant stirring at
37 C. Platelet aggregation was assayed by light transmission
in a PAP-4 aggregometer (Bio-Data, Alpha Laboratories,
Eastleigh, UK) in triplicate. PPP and JNL buffer were used as
the 100% light transmission references for PRP and washed
platelets respectively. The pharmacological protease activated
receptor type 1 agonist SFLLRNeNH2 (0.1 mM; Clinalfa,
La¨ufelfingen, Switzerland) and adenosine diphosphate (ADP,
5 mM; Trinity Biotech, Wicklow, Ireland) were used as agonist
positive controls. The lag time to platelet aggregation was
measured as the time from addition of agonist to the initiation
of platelet aggregation up to a 25 min limit. The maximal
percentage platelet aggregation was also determined.2.9. Flow cytometry
2.9.1. Bacteriumeplatelet adhesion
S. aureuseplatelet adhesion was measured following
incubation of 9  107 Hoechst 33342-labeled bacterial cells
with 9  106 platelets in PRP at room temperature for 5 min,
followed by labeling with 1% fluorescein isothiocyanate
(FITC)-conjugated mouse anti-human CD42a antibody
(Serotec, Kidlington, UK) for 30 min, and fixing with 1 ml 1%
(v/v) paraformaldehyde. Fluorescent data were determined
within 24 h of fixation using a FACSVantage SE cell sorter
(Becton Dickinson, Oxford, UK) with FACSDiVa software
(Becton Dickinson, Oxford, UK). One hundred thousand
platelets were collected for each sample and distilled water,
flow buffer (Becton Dickinson, Oxford, UK) and Tris buffer
served as negative controls. S. aureus bound to platelets were
identified as cells positive for both Hoechst and FITC fluo-
rescent signals, and data were analyzed using FlowJo v 8.8.6
(Tree Star Inc., OR, USA) to determine the percentage of
platelets bound to S. aureus and the percentage of S. aureus
cells bound to platelets [24].2.9.2. In vivo and in vitro platelet activation
Within 5 min of transfer into a D-phenylalanyl-L-propyl-L-
arginine chloromethylketone tube, blood was labeled at room
temperature with the appropriate monoclonal antibodies for
determination of in vivo platelet activation [26,27]. Briefly,
mouse anti-human CD14-phycoerythrin (PE; Inverness
Medical, Stockport, UK) and anti-CD42a-FITC were added to
60 ml of blood at a 1:40 dilution for detection of plate-
letemonocyte aggregates (PMA). Anti-CD42a-FITC and
mouse anti-human CD62P-PE (Serotec, Kidlington, UK) at
a 1:2 dilution were used to label 5 ml of blood for detection of
platelet P-selectin expression. The appropriate isotope mouse
IgG1 antibodies (Serotec, Kidlington, UK) and flow buffer
served as negative controls. Following 20 min of immuno-
labelling, PMA samples were fixed with 500 ml FACS lyse
Table 1
Clinical characteristics of 40 recruited patients with infective endocarditis.
Clinical feature Number (%)
Age, y 56  17
Male 30 (75)
Time from diagnosis to study participation 12  15 d
Type of valve
Native 26 (65)
Prosthetic 14 (35)
Bioprosthetic 8
Mechanical 6
Valvular heart disease 14 (35)
Congenital heart disease 8
Bicuspid aortic valve 4
Rheumatic heart disease 1
Degenerative valve 1
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samples with 1.425 ml 1% (v/v) paraformaldehyde.
Platelet activation was quantified within 24 h of sample
fixation using dual-channel flow cytometry (FACSCalibur,
Becton Dickinson, Oxford, UK) with at least 2000 monocytes
and 7500 platelets collected for each assay. PMAs were
defined as monocytes expressing CD14 that were also positive
for CD42a, and P-selectin-expressing platelets were defined as
platelets that were positive for CD62P. Data were acquired and
analyzed using CellQuest software (Becton Dickinson,
Oxford, UK), and results expressed as a percentage of the
monocyte or platelet cell population respectively.
For determination of agonist-induced platelet P-selectin
expression in vitro, bacterial suspensions were added to PRP
at a ratio of 10:1, incubated for 30 min at room temperature,
and labeled with 2% anti-CD42a-FITC, anti-CD62P-PE or
the appropriate IgG1 isotype control for 30 min. Samples
were fixed with 1 ml 1% (v/v) paraformaldehyde, and platelet
P-selectin expression was determined as described above
using a FACScan flow cytometer (Becton Dickinson, Oxford,
UK). SFLLRNeNH2 (1 mM) was used as a positive control.Previous infective endocarditis 6 (15)
Intravenous drug abuse 4 (10)
Affected valve(s)2.10. Immobilized plasma protein adherence assaysMitral 16 (40)
Aortic 13 (32)
Mitral þ aortic 6 (15)
Tricuspid  mitral or aortic 4 (10)
Pulmonary 1 (3)
Organism(s)
Streptococci 15 (37)
Viridans streptococci 11
Non-viridans streptococci 4
Staphylococci 11 (28)
Staphylococcus aureus 8
Coagulase-negative staphylococci 3
Streptococci þ staphylococci 2 (5)
Enterococci 2 (5)
Othera 7 (17)
Culture-negative 3 (8)
Vegetation
Present 31 (78)
Length, mmb 15  8
Width, mmb 9  4
Surgery 25 (63)
Replacement 19
Repair 5Adherence of bacteria to immobilized fibrinogen and
fibronectin was performed as previously described [25,28].
Briefly, 96-well flat-bottomed plates (Nunc, Loughborough,
UK) were coated with serial dilutions of 100 ml of
0e50 mg/ml human fibrinogen or bovine fibronectin in PBS,
and incubated at 4 C overnight. Plates were thrice washed
with 100 ml PBS, and then incubated with 100 ml of 2 mg/ml
filter-sterilised bovine serum albumin (Sigma, Dorset, UK) for
1 h at 37 C. S. aureus cells (1.25  108) were added to each
well and incubated for 2 h at 37 C under constant rotation,
fixed with 100 ml 25% (v/v) formaldehyde (VWR, Lutter-
worth, UK) for 30 min at room temperature, stained with
100 ml 0.5% (w/v) crystal violet (Sigma, Dorset, UK) for
1 min, and washed three times with 100 ml PBS between each
fixing or staining stage. The absorbance at 590 nm (A590) was
determined in an enzyme-linked immunosorbent assay
(ELISA) plate reader (VERSAmax microplate reader,
Molecular Devices, Wokingham).Replacement þ repair 1
Embolic phenomenac 15 (38)2.11. Statistical analysis
Cerebral 8
Splenic 3
Pulmonary 2
Spinal 2
Renal 2
Heart failure 12 (30)
Death 9 (23)
Composite clinical end-pointd 30 (75)
a Other organisms isolated include Aerococcus urinae, Aerococcus viridans,
Gemella sanguinis, Granulicatella adiacens, Haemophilus parainfluenzae,
Propionibacterium acnes and Serratia marcescens (n ¼ 1 for each).
b Vegetation characteristics were determined for 30 subjects.
c 2 subjects had more than one site of embolism.
d The clinical end-point represents a composite of embolism, heart failure,
need for surgery and mortality.Data analysis was performed using SPSS v. 16.0 (SPSS
Inc, Chicago, IL, USA) for Macintosh. The chi-squared test
was used to compare polymorphism frequencies and the
normality of data distribution was determined using the
ShapiroeWilk test. The KruskaleWallis and ManneWhitney
U tests were used to analyze the relationship between platelet
receptor genotype and numerical data, while Fisher’s exact
and the chi-squared tests were used to determine the corre-
lation between platelet receptor polymorphisms and categor-
ical variables. Statistical significance was taken as two-sided
P < 0.05 for all analyses. Values are expressed as
mean  standard deviation.3. Results3.1. Characteristics of the study populationClinical characteristics of 40 recruited patients with infective
endocarditis (75% male, 56  17 y) are outlined in Table 1.
220 S. Daga et al. / Microbes and Infection 13 (2011) 216e225Patients were recruited into the study 12 15 d after diagnosis.
The mitral or aortic valves were affected in 87% of cases, with
streptococci and staphylococci collectively accounting for 70%
of cases of infective endocarditis. Just over a third of patients
had underlying valvular heart disease or prosthetic valves, 15%
had a past history of infective endocarditis and 10% were
intravenous drug abusers. Vegetations were identified in 78% of
subjects, and vegetation dimensions were measured in 97% of
patients using transthoracic or transesophageal echocardio-
graphic images acquired 7  8 d after diagnosis. Clinically
detected emboli were present in 38% of cases, heart failure in
30%, 63% required surgical treatment and the mortality rate in
our patient cohort was 23%. The composite clinical end-point of
embolism, heart failure, need for surgery and heart failure was
present in 75% of patients. Out of the 160 healthy volunteers,
33% were male with a mean age of 30  10 y.3.2. Susceptibility to infective endocarditisTable 3
Baseline demographics and clinical outcome in 39 patients with infective
endocarditis stratified by the GPIIIa PlA1/A2 platelet receptor genotype.
GPIIIa PlA1/A2 genotype P valuea
A1/A1, n ¼ 29 A1/A2, n ¼ 10
Age (y) 56  17 56  17 0.949
Male (%) 22 (76) 8 (80) 1.000
Native valve (%) 20 (69) 6 (60) 0.704
Valvular heart disease (%) 8 (28) 5 (50) 0.254We determined the distribution of the GPIIIa PlA1/A2 and
FcgRIIa H131R polymorphisms in patients with infective
endocarditis and all allelic variants were in HardyeWeinberg
equilibrium (P ¼ 0.686 and P ¼ 0.770, respectively). The
distribution of GPIIIa PlA1/A2 and FcgRIIa H131R platelet
receptor genotype did not vary between patients with infective
endocarditis and healthy volunteers (P ¼ 0.675 and P ¼ 0.774
respectively; Table 2), and were consistent with findings from
previous studies of platelet receptor polymorphisms [13,19,28].Previous infective
endocarditis (%)
2 (7) 3 (30) 0.096
Intravenous drug
abuser (%)
3 (10) 1 (10) 1.000
3.3. In vivo platelet activation and clinical outcomeAffected valve (%)
Mitral 11 (38) 4 (40) 0.524
Aortic 10 (35) 3 (30)
Mitral þ aortic 5 (17) 1 (10)
Tricuspid  mitral/aortic 3 (10) 1 (10)
Pulmonary 0 1 (10)
Presence of vegetations (%) 22 (76) 8 (80) 1.000We analyzed the association of GPIIIa PlA1/A2 and FcgRIIa
H131R genotype with in vivo platelet activation and clinical
characteristics in patients with infective endocarditis. Given
the modest study population, a composite clinical end-point
was used.Table 2
Frequencies of the platelet receptor GPIIIa PlA1/A2 and FcgRIIa H131R
polymorphisms in 40 patients with infective endocarditis compared to 160
healthy volunteers.
Platelet
receptor
genotype
Infective
endocarditis
patients,
n ¼ 40 (%)
Healthy
volunteers,
n ¼ 160 (%)
P valuea Healthy
volunteers
n ¼ 88b
Healthy
volunteers
n ¼ 31c
GPIIIa PlA1/A2
PlA1/A1 29 (72%) 126 (78%) 0.675 58 17
PlA1/A2 10 (25%) 30 (19%) 26 10
PlA2/A2 1 (3%) 4 (3%) 4 4
FcgRIIa H131R
H/H 11 (28%) 39 (24%) 0.774 23 7
H/R 19 (47%) 72 (45%) 40 16
R/R 10 (25%) 49 (31%) 25 8
a The P value was determined using the chi-squared test.
b Platelet receptor genotype for healthy volunteers selected for platelet
aggregation studies using PRP.
c Platelet receptor genotype for healthy volunteers selected for flow cyto-
metric studies and platelet aggregation studies using washed platelets.Baseline demographic variables for subjects stratified by
GPIIIa PlA1/A2 genotype are outlined in Table 3. As only one
subject had the PlA2/A2 genotype, data for this individual were
excluded from all analyses. Apart from an association of the
GPIIIa PlA1/A1 genotype with infection by staphylococci or
streptococci (P ¼ 0.030; Table 3), the GPIIIa PlA1/A2 poly-
morphism did not influence background factors in patients with
infective endocarditis. The GPIIIa PlA1/A1 genotype was asso-
ciated with increased in vivo platelet activation (P ¼ 0.001 for
PMA and P ¼ 0.026 for platelet P-selectin expression; Fig. 1)
and reduced embolism (P ¼ 0.027; Table 3). However, there
were no correlations of the GPIIIa PlA1/A2 polymorphism with
vegetation characteristics or the composite clinical end-point of
embolism, heart failure, need for surgery or mortality (P> 0.05
for all).
Demographic variables for patients with infective endo-
carditis, categorized by FcgRIIa H131R genotype, are depicted
in Table 4. Apart from an association of the R131 allele with
solitary aortic valve infection (P ¼ 0.005), clinicalVegetation length, mmb 14  5 20  12 0.166
Vegetation width, mmb 9  4 9  3 0.946
Organism (%)
Streptococci 13 (45) 2 (20) 0.030
Staphylococci 10 (35) 1 (10)
Streptococci þ staphylococci 2 (7) 0 (0)
Enterococci 1 (3) 1 (10)
Other 2 (7) 5 (50)
Culture negative 1 (3) 1 (10)
Surgery (%) 18 (62) 7 (70) 0.721
Embolic phenomena (%) 8 (28) 7 (70) 0.027
Heart failure (%) 10 (34) 1 (10) 0.228
Death (%) 6 (21) 3 (30) 0.669
Composite clinical
end-point (%)c
22 (73%) 8 (80%) 1.000
a P values were determined using the ManneWhitney U test for numerical
variables, and Fisher’s exact test or the chi-squared test for categorical vari-
ables. Data for the one PlA2/A2 subject are not depicted and were excluded
from all analyses.
b Data on vegetation characteristics were available for 29 of the 30 subjects
with vegetations.
c The clinical end-point represents a composite of embolism, heart failure,
need for surgery and mortality.
Fig. 1. Association between GPIIIa PlA1/A2 genotype and platelet activation in
patients with infective endocarditis. Data for the one PlA2/A2 patient are not
depicted. PMA, plateletemonocyte aggregates. P values were determined
using the ManneWhitney U test.
Table 4
Baseline demographics and clinical outcome in 40 patients with infective
endocarditis stratified by the FcgRIIa H131R platelet receptor polymorphism.
FcgRIIa H131R genotype P valuea
H/H,
n ¼ 11
H/R,
n ¼ 19
R/R,
n ¼ 10
Age (y) 56  13 59  18 49  21 0.470
Male (%) 6 (55) 15 (79) 9 (90) 0.149
Native
valve (%)
8 (73) 10 (53) 8 (80) 0.279
Valvular heart
disease (%)
7 (64) 5 (26) 2 (20) 0.061
Previous infective
endocarditis (%)
3 (27) 2 (11) 1 (10) 0.408
Intravenous
drug abuser (%)
0 3 (16) 1 (10) 0.381
Affected valve (%)
Mitral 5 (45) 7 (37) 4 (40) 0.005
Aortic 0 11 (58) 2 (20)
Mitral þ aortic 5 (45) 0 1 (10)
Tricuspid  mitral/aortic 1 (10) 1 (5) 2 (20)
Pulmonary 0 0 1 (10)
Presence of
vegetations (%)
9 (82) 14 (74) 8 (80) 0.856
Vegetation
length, mmb
21  14 13  5 16  7 0.166
Vegetation
width, mmb
8  2 8  4 10  5 0.946
Organism (%)
Streptococci 4 (37) 6 (32) 5 (50) 0.545
Staphylococci 2 (18) 6 (32) 3 (30)
Streptococci þ 1 (9) 1 (5) 0
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Platelet activation, measured as both PMA and platelet
P-selectin expression, did not vary with FcgRIIa H131R geno-
type (P ¼ 0.656 and P ¼ 0.891 respectively; data not shown).
Although the H/R genotype was associated with reduced need
for surgery (P ¼ 0.005; Table 4) and the H131 allele with the
development of heart failure (P¼ 0.024; Table 4), there were no
correlations between FcgRIIa H131R genotype, vegetation
characteristics or the composite clinical end-point.staphylococci
Enterococci 2 (18) 0 0
Other 1 (9) 4 (21) 2 (20)3.4. Bacteriumeplatelet interactions in vitroCulture negative 1 (9) 2 (10) 0
Surgery (%) 10 (91) 7 (37) 8 (80) 0.005
Embolic
phenomena (%)
2 (18) 8 (42) 5 (50) 0.274
Heart failure (%) 6 (55) 6 (32) 0 0.024
Death (%) 4 (36) 5 (26) 0 0.118
Composite clinical
end-point (%)c
10 (91%) 12 (63%) 8 (80%) 0.219
a P values were determined using the KruskaleWallis test with Manne
Whitney U correction for numerical variables and the chi-squared test for cate-
gorical variables.
b Data on vegetation characteristics were available for 30 of 31 subjects with
vegetations.
c The clinical end-point represents a composite of embolism, heart failure,
need for surgery and mortality.In order to investigate the influence of platelet receptor
polymorphisms on S. aureuseplatelet interactions, we exam-
ined S. aureuseplatelet adhesion, activation and aggregation
in vitro using platelets from healthy volunteers of different
GPIIIa PlA1/A2 and FcgRIIa H131R genotype (Table 2). In
total, six different bacterial preparations, including S. aureus
strain Newman and two clinical isolates from infective endo-
carditis (strains 207 and 209), grown to both exponential and
stationary phases of growth, were used in platelet interaction
studies. S. aureus strain 207 grown to stationary phase did not
induce platelet aggregation within 25 min and was therefore
not utilized as an agonist in further S. aureuseplatelet inter-
action studies. The S. aureus strains employed exhibited
differences in the capacity to adhere to immobilized fibrinogen
and fibronectin in vitro (Fig. 2). In the exponential phase of
growth, strain Newman demonstrated weak binding to fibro-
nectin, and strain 207 did not adhere to fibronectin at all. In
stationary phase, all three strains adhered to fibrinogen with
the highest affinity exhibited by strain Newman (Fig. 2).
Platelet aggregometry was performed with PRP obtained
from 88 of the 160 healthy volunteers (40% male, 30  9 y),
selected to represent different GPIIIa PlA1/A2 and FcgRIIa
H131R genotypes (Table 2). Results obtained using PlA2/A2
platelets were excluded from all analyses given the small
number of subjects in this group (n¼ 4) and the highly variable
data (Table 5). An association of GPIIIa PlA1/A1 genotype withreduced lag time to aggregation (P ¼ 0.038) was apparent for
one of the six bacterial agonists examined (exponential phase
Newman; Table 5), while an increase in percentage aggregation
of GPIIIa PlA1/A1 platelets (P¼ 0.033) was observed for another
bacterial agonist (stationary phase 209; Table 5). Exponential
phase 209 was associated with reduced percentage aggregation
of platelets with the FcgRIIaR/R genotype (P¼ 0.043; Table 6).
For all other bacterial agonist preparations, there were no
differences in aggregation of platelets of differentGPIIIa PlA1/A2
or FcgRIIaH131R genotype in PRP (Tables 5 and 6), suggesting
that platelet receptor polymorphisms do not have a broad
influence on S. aureus-induced platelet aggregation. Notably,
percentage platelet aggregation did not vary with platelet
Fig. 2. Adherence of S. aureus strains to immobilized plasma proteins. Strains Newman (A), 207 (C), or 209 (-), were grown to exponential phase and
incubated with doubling dilutions of immobilized bovine fibronectin (A), or grown to stationary phase and incubated with doubling dilutions of immobilized
human fibrinogen (B). Adherence of strain Newman to wells incubated with BSA only was used to determine background levels (:).
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SFLLRNeNH2 (Tables 5 and 6).
In order to investigate the possibility that differences in
plasma protein and IgG concentration could influence sensi-
tivity to platelet aggregation [29,30], platelet aggregometry
was repeated with washed platelets isolated from 31 healthy
volunteers (52% male, 33  9 y) selected on the basis of their
platelet receptor genotype (Table 2). There were no significant
correlations between platelet receptor genotype and aggrega-
tion of washed platelets induced by S. aureus and pharmaco-
logical agonists (Tables 5 and 6), implying that the small
number of significant associations observed for specific
bacterial agonists in PRP may have been due to differences in
plasma protein concentrations in human volunteers.
Finally, in order to determinewhether the GPIIIa PlA1/A2 and
FcgRIIa H131R polymorphisms influence S. aureuseplatelet
adhesion or activation distinct from aggregation, flow cytom-
etry was performed using blood from the same 31 representa-
tive individuals used for washed platelet aggregation analysis
(Table 2). We discovered that GPIIIa PlA1/A2 and FcgRIIa
H131R genotype did not influence S. aureuseplatelet binding
or S. aureus-induced platelet activation (Tables 5 and 6).
4. Discussion
Previous studies have identified associations between
platelet receptor polymorphisms and susceptibility to vascular
and immune disease [15,16,19,20]. This is the first study to
investigate the association between platelet receptor genotype,
S. aureuseplatelet interactions and clinical outcome in
infective endocarditis. Overall, our data suggest that the
GPIIIa PlA1/A2 and FcgRIIa H131R platelet receptor poly-
morphisms do not have a major influence on S. aur-
euseplatelet adhesion, activation and aggregation in vitro or
prognosis in infective endocarditis.
The GPIIIa PlA1/A2 and FcgRIIa H131R platelet receptor
polymorphisms did not influence S. aureuseplatelet adhesion
or activation in vitro. However, highly variable strain-dependent
effects on S. aureus-induced platelet aggregation wereobserved, highlighting the dynamic interaction between host
and pathogen that may influence the outcome of infection [11].
Considerable differences in the capacity to induce platelet
aggregation exist among S. aureus clinical isolates, likely
reflecting variation in MSCRAMM expression [23,25,31]. For
example, strain 209 induced more rapid platelet aggregation in
the exponential phase compared to the stationary phase of
growth, while the converse was true for strain Newman (Tables
5 and 6). This is consistent with our knowledge of the
predominant role of fibronectin-binding proteins (Fnbps), in
S. aureus-induced platelet aggregation during the exponential
phase of growth, as strain 209 adhered strongly to fibronectin
whereas strain Newman does not express functional Fnbps and
binds fibronectin weakly (Fig. 2) [32]. In addition, strain 207
did not induce rapid platelet aggregation in exponential phase,
consistent with its complete lack of fibronectin-binding activity
(Fig. 2). In the stationary phase of growth, the fibrinogen-
binding protein clumping factor A (ClfA) is regarded as the
predominant surface protein involved in platelet aggregation
[33]. However, strains 207 and 209 had long lag times to platelet
aggregation in stationary phase, in spite of their capacity to bind
to fibrinogen (Fig. 2), but both strains demonstrated lower
adherence compared to strain Newman, possibly reflecting
lower levels of expression of ClfA on the bacterial cell surface.
The associations between GPIIIa PlA1/A2 and FcgRIIa
H131R genotype and S. aureus-induced platelet aggregation in
PRP were lost when washed platelets were used, suggesting
that variation in the concentration of immunoglobulins or
plasma proteins such as fibrinogen, fibronectin or von Wille-
brand factor may have influenced our results [11,29].
Our data are consistent with previous studies that have
demonstrated a lack of effect of the FcgRIIa H131R genotype
on shear-induced platelet activation and platelet aggregation
induced by both pharmacological agonists and streptococci
[18,30]. However, our observations contrast with those of large
studies that have demonstrated increased platelet activation
and aggregation in response to ADP and epinephrine in PlA2
carriers. This may be due to the use of bacterial agonists and
saturating concentrations of pharmacological agonists in the
Table 5
Correlation between GPIIIa PlA1/A2 genotype and S. aureus-induced platelet
aggregation, activation and S. aureuseplatelet binding using blood from
selected healthy volunteers.
Agonist GPIIIa PlA1/A2 genotype P valuea
A1/A1 A1/A2 A2/A2
Platelet-rich plasma (n [ 88)
Lag time, min
Newman, stationary 1.92  0.65 1.83  0.47 2.63  1.25 0.965
209, stationary 8.60  3.51 12.44  7.28 6.08  1.41 0.862
Newman, exponential 6.07  1.41 6.60  1.26 6.92  1.03 0.038
207, exponential 9.19  3.36 9.11  3.62 8.31  5.14 0.642
209, exponential 1.94  0.64 1.84  0.50 3.13  1.82 0.768
Platelet aggregation, %
Newman, stationary 67  10 69  7 66  2 0.809
209, stationary 68  8 64  10 63  33 0.033
Newman, exponential 69  12 60  19 76  7 0.091
207, exponential 66  15 66  13 70  16 0.595
209, exponential 63  9 63  14 67  4 0.642
ADP 69  12 74  12 70  6 0.074
SFLLRNeNH2 68  12 69  13 69  7 0.762
Washed platelets (n [ 31)
Lag time, min
Newman, stationary 3.00  0.90 2.89  1.26 9.21  10.56 0.553
209, stationary 10.20  8.73 9.10  9.18 13.66  7.88 0.418
Newman, exponential 8.65  8.02 9.05  9.16 21.01  7.99b 0.829
207, exponential 25c 19.24  8.78 22.93  4.14b N/Ad
209, exponential 7.74  5.48 8.74  7.43 16.32  10.10 0.979
Platelet aggregation, %
Newman, stationary 82  4 80  6 78  5 0.590
209, stationary 73  12 77  7 73  17 0.692
Newman, exponential 66  16 75  6 78b 0.314
209, exponential 71  12 72  8 75  1 0.830
ADP 29  20 36  17 12  16 0.215
SFLLRNeNH2 71  19 75  5 64  22 0.306
Agonist-induced platelet activation, % (n [ 31)
Newman, stationary 55  29 49  25 43  33 0.711
209, stationary 26  11 18  11 24  6 0.093
Newman, exponential 36  20 40  19 31  16 0.604
207, exponential 24  15 18  12 25  11 0.443
209, exponential 28  17 20  12 21  4 0.223
SFLLRNeNH2 82  14 83  6 78  14 0.660
Percentage of platelets bound to S. aureus, % (n [ 31)
Newman, stationary 84  21 85  26 91  8 0.792
209, stationary 86  22 86  23 92  8 0.874
Newman, exponential 58  27 53  26 70  31 0.751
207, exponential 78  25 74  28 77  20 0.426
209, exponential 57  25 52  28 58  19 0.598
Percentage of S. aureus cells bound to platelets, % (n [ 31)
Newman, stationary 49  10 44  15 56  9 0.312
209, stationary 44  12 38  12 48  12 0.200
Newman, exponential 22  12 18  11 25  8 0.711
207, exponential 24  10 21  8 23  3 0.339
209, exponential 18  11 14  7 17  3 0.419
Percentage platelet aggregation in response to strain 207 grown to exponential
phase could not be analyzed when using washed platelets, as aggregation was
only observed with platelets isolated from 2 subjects. Data for S. aureus strain
207 at stationary phase of growth were not analyzed as platelet aggregation
was not observed in response to this agonist.
a P values were determined using the ManneWhitney U test comparing the
PlA1/A1 to the PlA1/A2 genotype.
b Only one PlA2/A2 subject’s washed platelets aggregated in response to
S. aureus strains Newman and 207 at the exponential phase of growth.
c Lag times of 25 min represent absence of platelet aggregation.
d Statistical analyses could not be performed as platelet aggregation was not
observed with PlA1/A1 platelets in response to strain 207 at the exponential
phase of growth.
Table 6
Correlation between FcgRIIa H131R genotype and S. aureus-induced platelet
aggregation, activation and S. aureuseplatelet binding using blood from
selected healthy volunteers.
Agonist FcgRIIa H131R genotype P valuea
H/H H/R R/R
Platelet-rich plasma (n [ 88)
Lag time, min
Newman, stationary 1.82  0.58 1.94  0.68 2.02  0.69 0.384
209, stationary 8.02  3.69 8.31  3.85 9.91  4.00 0.287
Newman, exponential 5.90  1.61 6.67  1.29 5.92  1.07 0.077
207, exponential 9.28  3.64 9.18  3.60 8.87  3.23 0.765
209, exponential 1.86  0.51 1.92  0.64 2.16  1.01 0.401
Platelet aggregation, %
Newman, stationary 69  9 68  8 65  10 0.351
209, stationary 68  9 67  10 64  14 0.611
Newman, exponential 70  14 65  17 66  9 0.285
207, exponential 69  10 64  17 66  13 0.576
209, exponential 65  6 65  8 57  15 0.043
ADP 73  11 70  13 69  11 0.206
SFLLRNeNH2 65  15 70  12 68  9 0.275
Washed platelets (n [ 31)
Lag time, min
Newman, stationary 3.26  0.66 3.19  1.18 5.42  7.96 0.949
209, stationary 9.00  8.18 9.59  8.13 12.81  10.31 0.948
Newman, exponential 11.98  10.44 8.74  8.19 12.61  10.42 0.328
207, exponential 23.62  3.38 22.85  5.98 22.82  6.18 0.536
209, exponential 9.57  7.90 9.29  7.23 8.68  7.26 0.332
Platelet aggregation, %
Newman, stationary 81  3 79  5 85  4 0.066
209, stationary 75  6 73  14 77  8 0.385
Newman, exponential 69  5 75  5 56  22 0.207
209, exponential 76  3 69  13 74  5 0.251
ADP 33  31 29  16 26  19 0.877
SFLLRNeNH2 75  7 71  7 68  18 0.622
Agonist-induced platelet activation, % (n [ 31)
Newman, stationary 64  29 54  27 40  25 0.294
209, stationary 27  12 22  12 23  9 0.834
Newman, exponential 49  24 38  16 25  15 0.059
207, exponential 31  22 19  11 22  10 0.450
209, exponential 34  23 23  14 21  6 0.410
SFLLRNeNH2 78  23 84  6 79  11 0.473
Percentage of platelets bound to S. aureus, % (n [ 31)
Newman, stationary 87  23 87  18 80  26 0.456
209, stationary 84  28 90  16 82  25 0.544
Newman, exponential 56  30 60  29 57  34 0.964
207, exponential 75  31 81  21 70  27 0.476
209, exponential 51  27 59  23 51  30 0.730
Percentage of S. aureus cells bound to platelets, % (n [ 31)
Newman, stationary 52  9 48  13 47  14 0.768
209, stationary 47  13 42  12 40  12 0.550
Newman, exponential 21  6 22  14 19  9 0.896
207, exponential 20  6 25  10 22  7 0.699
209, exponential 17  1 18  11 15  5 0.591
Percentage platelet aggregation in response to strain 207 grown to exponential
phase could not be analyzed when using washed platelets, as aggregation was
only observed with platelets isolated from 2 subjects. Data for S. aureus strain
207 at stationary phase of growth were not analyzed as platelet aggregation
was not observed in response to this agonist.
a P values were determined using the KruskaleWallis test.
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PlA2/A2 genotype [17].
Consistent with our in vitro experiments and large studies
that have examined the role of platelet receptor polymorphisms
in thrombosis, immune disease and intravascular device
224 S. Daga et al. / Microbes and Infection 13 (2011) 216e225infection, GPIIIa PlA1/A2 and FcgRIIa H131R genotype did not
influence the development of infective endocarditis, vegetation
characteristics or the composite clinical end-point of embolism,
heart failure, need for surgery or mortality [16,34e36].
Notably, the demographics of our infective endocarditis study
population were similar to those observed in large multi-center
published studies [2,37], but rates of staphylococcal endo-
carditis and vegetation formation were lower than expected,
possibly due to a reduced prevalence of S. aureus infection in
comparison to the USA [2,4,37]. Rates of heart failure, embo-
lism and mortality were comparable to other published
research, while rates of surgery were higher than reported by
Murdoch et al., most likely attributable to the Edinburgh Royal
Infirmary being a tertiary referral center for cardiothoracic
surgery [2,38].
In contrast to our in vitro analysis, we identified increased
platelet activation in patients with infective endocarditis
homozygous for the PlA1 allele, suggesting that the PlA1/A1
genotype may influence bacteriumeplatelet interactions in
vivo. However, an effect of the differing demographics of our
study populations, which included predominantly older male
infective endocarditis patients and a cohort of mostly younger
female healthy volunteers, cannot be ruled out, particularly as
it is known that platelet activation increases with age and in
female subjects [39,40]. It is also possible that the low shear
environment encountered during platelet aggregometry in
vitro, in contrast to the high shear environment in vivo, may
influence S. aureuseplatelet interactions [41]. Furthermore, it
is possible that the growth of S. aureus in human blood in
vivo, as opposed to nutrient-rich culture medium in vitro, may
influence the expression of MSCRAMMs implicated in
bacterium-induced platelet activation [42,43].
Finally, it is important to note that the current study had
a modest patient population size, particularly with regards to
the PlA2/A2 genotype. A larger study would also enable
correction for possible confounding factors such as age,
gender, ethnicity, antibiotic treatment, platelet receptor
density, source of infection and underlying cardiac and
bacteremic risk factors for infective endocarditis [22]. In
particular, correction for pathogen-related factors such as route
of acquisition and bacterial species would be desirable.
Nevertheless, the combination of approaches employed here,
including the analysis of samples from well-defined clinical
cases of infective endocarditis and in vitro platelet functional
analyses, strongly suggest that the GPIIIa PlA1/A2 and FcgRIIa
H131R platelet receptor polymorphisms do not influence S.
aureuseplatelet interactions in vitro and do not constitute risk
factors for infective endocarditis.
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